Daily Suppressive Therapy for Genital Herpes in Adults
For daily suppressive therapy of genital herpes in immunocompetent adults, use acyclovir 400 mg orally twice daily, valacyclovir 500 mg orally once daily (or 1000 mg once daily), or famciclovir 250 mg orally twice daily. 1
Primary Dosing Options
The CDC guidelines provide multiple equivalent regimens for daily suppressive therapy 1:
- Acyclovir 400 mg orally twice daily 1
- Valacyclovir 500 mg orally once daily 1
- Valacyclovir 1000 mg orally once daily 1
- Valacyclovir 250 mg orally twice daily 1
- Famciclovir 250 mg orally twice daily 1
Choosing Between Regimens
Valacyclovir and famciclovir offer superior convenience with once or twice-daily dosing compared to acyclovir, which is an important consideration for long-term adherence. 1
Important Caveat for High-Frequency Recurrences
Valacyclovir 500 mg once daily is less effective in patients with ≥10 recurrences per year and should be avoided in this population. 1, 2 For these patients, use valacyclovir 1000 mg once daily, valacyclovir 250 mg twice daily, famciclovir 250 mg twice daily, or acyclovir 400 mg twice daily instead 1, 2.
Efficacy and Safety Data
Daily suppressive therapy reduces recurrence frequency by ≥75% in patients with frequent recurrences (≥6 episodes per year) 1. Safety and efficacy have been documented for acyclovir for up to 6 years of continuous use 1, 3. Valacyclovir and famciclovir have documented safety for 1 year of continuous use 1.
Research demonstrates that 65-69% of patients remain completely recurrence-free during suppressive therapy 4. Suppressive therapy does not eliminate asymptomatic viral shedding but reduces it 1.
Duration and Reassessment
After 1 year of continuous suppressive therapy, discontinue treatment temporarily to reassess the patient's recurrence rate, as the frequency of recurrences naturally decreases over time in many patients. 1
Special Populations
HIV-Infected Patients
HIV-infected patients require higher doses: valacyclovir 500 mg twice daily (not once daily), or acyclovir 400 mg orally 3-5 times daily. 1, 5 The once-daily valacyclovir 500 mg regimen used in immunocompetent patients is insufficient for HIV-infected individuals 5.
Pregnancy
Acyclovir is the preferred agent during pregnancy due to the most extensive safety data 5. Suppressive therapy starting at 36 weeks gestation is recommended for pregnant patients with a history of genital herpes 6.
Key Clinical Pearls
- Suppressive therapy has not been associated with clinically significant acyclovir resistance in immunocompetent patients 1
- Both episodic and suppressive therapy improve quality of life, but suppressive therapy provides greater reduction in disease burden and frequency 7
- Suppressive therapy in serodiscordant couples reduces transmission risk 6
- All three medications (acyclovir, valacyclovir, famciclovir) are comparable in clinical outcomes 1